Partnerships, alliances and recognitionĪstraZeneca will present new data across its diverse portfolio of cancer medicines at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) Congress 2021.Ī total of 14 approved and potential new medicines from AstraZeneca will be featured across more than 100 abstracts at the two meetings.Spira, 12 Takahiro Kogawa 13ġMassachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, MA.ģThe University of Texas MD Anderson Cancer Center, Houston, TX.ĤSouth Texas Accelerated Research Therapeutics, San Antonio, TX.ħNational Cancer Center Hospital East, Kashiwa, Japan.ĨDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA.ĩNational Cancer Center Hospital, Tokyo, Japan.ġ0Sarah Cannon Research Institute, Nashville, TN.ġ1Tennessee Oncology, PLLC, Nashville, TN.ġ2Virginia Cancer Specialists (VCS) Research Institute, Fairfax, VA.ġ3Department of Advanced Medical Development, Cancer Institute Hospital of JFCR, Tokyo, Japan. Tolcher, 4,5,6 Toru Mukohara, 7 Aaron Lisberg, 8 Toshio Shimizu, 9 Erika P. Krop, 2 Funda Meric-Bernstam, 3 Anthony W. The phase 3 randomized TROPION-Breast02 (NCT05374512) trial of Dato-DXd vs chemotherapy as 1L therapy for pts with metastatic TNBC is ongoing.Īditya Bardia, 1 Ian E. A median DOR of 16.8 months in each patient group and a median survival of 13.5 months in all treated patients and 14.3 months in Topo I inhibitor–naive patients were observed.ĭato-DXd demonstrated encouraging and durable antitumor activity and a manageable safety profile in heavily pretreated pts with metastatic TNBC.No treatment-related deaths were observed.Īntitumor responses were observed in the majority of patients, with an ORR of 32% in all patients and 44% in patients who were treatment-naive to Topo I inhibitor–based ADC therapies and had measurable disease at baseline:.No cases of ILD, febrile neutropenia, or grade ≥3 diarrhea were reported.One patient experienced grade 3 decreased neutrophil count.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |